ArticleOncology letters2025
Primary pulmonary malignant melanoma with H3K27Me3 loss: A case report.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary pulmonary malignant melanoma (pPMM) is an exceptionally rare type of primary malignant tumor. The present study reports a unique case of pPMM in a 54-year-old woman. Surgical resection revealed a tumor localized around the bronchus, showing nodular growth with relatively well-defined borders and no evidence of local or distant metastasis. To further characterize this rare pPMM, histological analysis, immunohistochemistry, sanger sequencing and next-generation sequencing were conducted. Histologically, the tumor exhibited biphasic differentiation, with both epithelial-like and spindle cell-like features, as well as high-grade characteristics, including significant atypia, necrosis and a high mitotic index. Key diagnostic features of malignant melanoma were evident, including prominent red nucleoli and melanin pigmentation. Immunohistochemistry confirmed the presence of melanoma markers and demonstrated a loss of H3K27Me3 expression. The programmed death-ligand 1 positivity rate of the tumor was 60%. NGS identified a mutation in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.